[HTML][HTML] Clinical utility of SARS-CoV-2 serological testing and defining a correlate of protection

K Sobhani, S Cheng, RA Binder, NJ Mantis… - Vaccines, 2023 - mdpi.com
Herein, we review established clinical use cases for SARS-CoV-2 antibody measures, which
include diagnosis of recent prior infection, isolating high titer convalescent plasma …

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

M Zendt, FA Bustos Carrillo, S Kelly, T Saturday… - Science …, 2023 - science.org
Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people
(IDP) has focused on cancer and organ transplantation populations. In a prospective cohort …

Age-and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents

C Jay, E Adland, A Csala, N Lim, S Longet… - Frontiers in …, 2023 - frontiersin.org
Introduction The key to understanding the COVID-19 correlates of protection is assessing
vaccine-induced immunity in different demographic groups. Young people are at a lower risk …

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial

AL Figueroa, K Ali, G Berman, H Zhou, W Deng… - …, 2024 - thelancet.com
Background Longitudinal changes in vaccination-induced immune response remain
inadequately characterized in adolescents. We present long-term safety, immunogenicity …

[HTML][HTML] Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection

AC Dowell, G Tut, J Begum, R Bruton, C Bentley… - Journal of Infection, 2023 - Elsevier
Repeated coronavirus infections in childhood drive progressive maturation of systemic
immune responses into adulthood. Analyses of immune responses in children have focused …

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study

ND Almeida, I Schiller, D Ke, E Sakr, M Plesa… - Frontiers in …, 2024 - frontiersin.org
Background Vaccination against COVID-19 is highly effective in preventing severe disease
and hospitalization, but primary COVID mRNA vaccination schedules often differed from …

Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection

E Goguet, CH Olsen, WA Meyer III, S Ansari… - Frontiers in …, 2024 - frontiersin.org
Introduction We sought to determine pre-infection correlates of protection against SARS-
CoV-2 post-vaccine inzfections (PVI) acquired during the first Omicron wave in the United …

STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ. 1.1 and XBB. 1.5 in patients with inflammatory bowel disease

S Woelfel, J Dütschler, M König… - Alimentary …, 2023 - Wiley Online Library
Background Vaccine‐elicited immune responses are impaired in patients with inflammatory
bowel disease (IBD) treated with anti‐TNF biologics. Aims To assess vaccination efficacy …

A phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

PS Kulkarni, B Gunale, S Kohli, S Lalwani, S Tripathy… - Scientific reports, 2023 - nature.com
Due to waning immunity following primary immunization with COVID-19 vaccines, booster
doses may be required. The present study assessed a heterologous booster of SII-NVX …